Research programme: pseudomonas vaccine - GenVec
Alternative Names: AdOprF.RGD.Epi8 - GenVecLatest Information Update: 29 Jun 2017
At a glance
- Originator GenVec
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
Most Recent Events
- 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
- 24 Jun 2005 Preclinical trials in Cystic fibrosis-associated respiratory tract infections in USA (unspecified route)
- 24 Jun 2005 Preclinical trials in Pseudomonal infections in USA (unspecified route)